Silence Therapeutics plc (SLNCF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Silence Therapeutics plc (SLNCF) trades at $5.50 with AI Score 48/100 (Grade C). Silence Therapeutics plc is a biotechnology company focused on developing novel RNA therapeutics. Market cap: $779M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for SLNCF: SLNCF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SLNCF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SLNCF: 1/3 scored disciplines lean bearish. Dominant signal: Ken Griffin bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Silence Therapeutics plc (SLNCF) Healthcare & Pipeline Overview
Silence Therapeutics plc, a biotechnology firm headquartered in London, specializes in RNA therapeutics for hematology, cardiovascular, and metabolic diseases, leveraging its mRNAi GOLD platform to target specific genes. The company is currently in Phase I clinical trials for multiple product candidates and has collaboration agreements with major pharmaceutical companies.
What Is the Investment Thesis for SLNCF?
Silence Therapeutics presents a compelling, albeit high-risk, investment thesis centered on its innovative mRNAi GOLD platform and its pipeline of RNA therapeutics. The company's focus on hematology, cardiovascular, and metabolic diseases addresses significant unmet medical needs. The ongoing Phase I clinical trials for SLN360 and SLN124 represent key value inflection points. Successful trial outcomes could trigger significant stock appreciation. Strategic collaborations with AstraZeneca, Mallinckrodt, and Hansoh Pharmaceutical validate the potential of Silence Therapeutics' technology and provide non-dilutive funding. However, the company's negative profit margin of -15851.9% highlights its reliance on external funding and the inherent risks associated with drug development. Investors should closely monitor clinical trial results, partnership developments, and cash burn rate.
Based on FMP financials and quantitative analysis
SLNCF Key Highlights
Market capitalization of $779M reflects investor sentiment regarding the company's future potential in the RNA therapeutics market.
- Gross margin of 61.5% indicates the potential profitability of Silence Therapeutics' products upon commercialization, although this is offset by high R&D expenses.
- Phase I clinical trials underway for SLN360 and SLN124 represent near-term catalysts for potential value creation.
- Collaboration agreements with AstraZeneca, Mallinckrodt, and Hansoh Pharmaceutical provide financial support and validation of the company's technology.
- Beta of 1.35 suggests that the stock is more volatile than the overall market, reflecting the high-risk, high-reward nature of biotechnology investments.
Who Are SLNCF's Competitors?
SLNCF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BRIBF Brii Biosciences Limited | $0.13 | +0.00% | $93.8M | 46 |
| CMVLF Cellectis S.A. | $3.47 | +12.66% | $252M | 51 |
| GNFTF Genfit S.A. | $16.28 | -1.33% | $816M | 73 |
| HNSBF Hansa Biopharma AB (publ) | $3.70 | +0.00% | $369M | 63 |
| JWCTF JW (Cayman) Therapeutics Co. Ltd | $0.20 | +0.00% | $84.2M | 54 |
| RIGL Rigel Pharmaceuticals, Inc. | $45.09 | -3.97% | $834M | 84 |
| ZVRA Zevra Therapeutics, Inc. | $11.89 | -1.98% | $703M | 93 |
| TBPH Theravance Biopharma, Inc. | $16.95 | -0.24% | $878M | 95 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SLNCF's Key Strengths?
Proprietary mRNAi GOLD platform for targeted RNA interference.
- Strategic collaborations with major pharmaceutical companies.
- Clinical pipeline of product candidates in Phase I trials.
- Experienced management team with expertise in RNA therapeutics.
What Are SLNCF's Weaknesses?
High R&D expenses and negative profit margin.
- Reliance on external funding and partnerships.
- Early-stage clinical development with inherent risks of failure.
- OTC market listing may limit access to institutional investors.
What Could Drive SLNCF Stock Higher?
Phase I clinical trial results for SLN360 in cardiovascular disease (high lipoprotein).
- Phase I clinical trial results for SLN124 in non-transfusion dependent thalassemia.
- Phase I clinical trial results for SLN124 in myelodysplastic syndrome.
- Advancement of strategic collaborations with AstraZeneca, Mallinckrodt, and Hansoh Pharmaceutical.
- Expansion of the clinical pipeline into new therapeutic areas.
What Are the Key Risks for SLNCF?
Financial-distress signal — its Altman Z-Score of -3.83 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Failure of clinical trials for SLN360 and SLN124.
- Competition from other biotechnology companies developing RNA therapeutics.
- Regulatory hurdles and delays in clinical trial approvals.
- High R&D expenses and reliance on external funding.
- OTC market listing and limited liquidity.
What Are the Growth Opportunities for SLNCF?
- Expansion into New Therapeutic Areas: Silence Therapeutics has the opportunity to leverage its mRNAi GOLD platform to develop RNA therapeutics for a broader range of diseases beyond hematology, cardiovascular, and metabolic indications. This could include exploring applications in oncology, neurology, and infectious diseases. The global market for oncology therapeutics, for example, is projected to reach $200 billion by 2028, presenting a significant growth opportunity. This expansion would require further investment in R&D and strategic partnerships.
- Advancement of Clinical Pipeline: The successful completion of Phase I clinical trials for SLN360 and SLN124, followed by progression into Phase II and Phase III trials, represents a critical growth driver for Silence Therapeutics. Positive clinical data would validate the efficacy and safety of its RNA therapeutics, attracting further investment and partnership opportunities. The timeline for advancing these programs depends on trial outcomes and regulatory approvals, but represents a potential value inflection point within the next 2-3 years.
- Strategic Partnerships and Licensing Agreements: Silence Therapeutics can further expand its reach and accelerate the development of its RNA therapeutics through strategic partnerships and licensing agreements with larger pharmaceutical companies. These collaborations can provide access to additional funding, expertise, and commercialization capabilities. The company's existing partnerships with AstraZeneca, Mallinckrodt, and Hansoh Pharmaceutical demonstrate the potential for this growth strategy. Future partnerships could focus on specific therapeutic areas or geographic markets.
- Geographic Expansion: While currently headquartered in London, Silence Therapeutics has the opportunity to expand its operations into new geographic markets, particularly in North America and Asia. These regions represent significant growth opportunities due to their large patient populations, advanced healthcare infrastructure, and increasing investment in biotechnology research. Expansion into these markets would require establishing local offices, building relationships with key stakeholders, and navigating regulatory requirements.
- Development of Novel Delivery Technologies: Silence Therapeutics can enhance the effectiveness and broaden the applicability of its RNA therapeutics by investing in the development of novel delivery technologies. This could include exploring new lipid nanoparticle formulations, exosome-based delivery systems, or other innovative approaches to improve the targeting and uptake of siRNA molecules. Advances in delivery technology could enable the treatment of diseases in tissues and organs beyond the liver, expanding the potential market for Silence Therapeutics' platform.
What Threats Does SLNCF Face?
- Competition from other biotechnology companies developing RNA therapeutics.
- Regulatory hurdles and delays in clinical trial approvals.
- Patent disputes and intellectual property challenges.
- Unforeseen adverse events or safety concerns in clinical trials.
What Are SLNCF's Competitive Advantages?
- Proprietary mRNAi GOLD platform for targeted RNA interference.
- Strong intellectual property portfolio protecting its RNA therapeutic technologies.
- Established partnerships with major pharmaceutical companies, providing access to funding and expertise.
- Clinical pipeline of product candidates in Phase I trials, demonstrating progress towards commercialization.
What Does SLNCF Do?
Silence Therapeutics plc, founded as SR Pharma plc and rebranded in 2007, is a biotechnology company dedicated to the discovery and development of RNA therapeutics. The company's core technology is its mRNAi GalNAc Oligonucleotide Discovery (GOLD) platform, which is designed to precisely target disease-associated genes within the liver. This platform utilizes short interfering RNA (siRNA) molecules to harness the body's natural RNA interference mechanism, degrading messenger RNA (mRNA) molecules that encode specific disease-related proteins. Silence Therapeutics' pipeline includes several product candidates in clinical development. SLN360 is currently in Phase I clinical trials for treating cardiovascular disease associated with high lipoprotein levels. SLN124 is also in Phase I clinical trials for non-transfusion dependent thalassemia and myelodysplastic syndrome, as well as for the treatment of polycythemia vera. These programs reflect the company's focus on hematological and metabolic disorders. Strategic collaborations are a key component of Silence Therapeutics' business model. The company has partnerships with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases. Additionally, they collaborate with Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets aimed at silencing the complement cascade in complement-mediated disorders. A collaboration with Hansoh Pharmaceutical Group Company Limited focuses on developing siRNAs for three undisclosed targets using Silence's mRNAi GOLD platform. Silence Therapeutics is headquartered in London, United Kingdom.
What Products and Services Does SLNCF Offer?
- Develops RNA therapeutics for various diseases.
- Utilizes mRNAi GOLD platform to target disease-associated genes.
- Creates short interfering RNA (siRNA) molecules.
- Targets hematology, cardiovascular, and metabolic indications.
- Conducts Phase I clinical trials for SLN360 and SLN124.
- Collaborates with pharmaceutical companies for research and development.
How Does SLNCF Make Money?
- Develops and patents RNA therapeutic technologies.
- Out-licenses or co-develops therapeutic candidates with larger pharmaceutical companies.
- Generates revenue through upfront payments, milestone payments, and royalties on sales of partnered products.
What Industry Does SLNCF Operate In?
Silence Therapeutics operates within the rapidly evolving biotechnology industry, specifically in the RNA therapeutics segment. This market is characterized by intense competition, high R&D costs, and stringent regulatory requirements. Competitors include companies like BRIBF (Arrowhead Pharmaceuticals), CMVLF (Alnylam Pharmaceuticals), GNFTF (Ionis Pharmaceuticals), HNSBF (Dicerna Pharmaceuticals), and JWCTF (Arbutus Biopharma), each pursuing different RNA-based therapeutic approaches. Silence Therapeutics' mRNAi GOLD platform aims to differentiate itself through precise targeting and efficient delivery.
Who Are SLNCF's Key Customers?
- Patients suffering from hematological, cardiovascular, and metabolic diseases.
- Pharmaceutical companies seeking to expand their portfolios with novel RNA therapeutics.
- Research institutions and academic centers interested in collaborating on RNA research.
Company Profile
Silence Therapeutics plc operates in the Biotechnology industry within the Healthcare sector. It is headquartered in London, GB. The company is led by CEO Iain Gladstone Ross. SLNCF has traded publicly since 2012.
Key Financial Metrics
Return on assets is -74.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -11.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 9.83 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -15.4%, the inverse of the P/E and a quick read on earnings relative to price.
SLNCF Valuation & Market Position
With a $779M market cap, Silence Therapeutics plc sits in the small-cap segment of the market. Relative to its peer group, SLNCF's quantitative score of 48/100 is roughly in line with the peer average of 57/100.
Quarterly Financial Performance: Silence Therapeutics plc
Revenue for Silence Therapeutics plc came in at $422K during Q1 2026, a 1141.2% improvement versus the preceding quarter. The company recorded a net loss of $15.0M, with diluted EPS of $-0.11. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare.
Financial Health
Silence Therapeutics plc's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -3.83 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Silence Therapeutics plc has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 12.6% below estimates on average.
Forward Outlook
Wall Street analysts project Silence Therapeutics plc revenue of about $11.9M for fiscal 2026, with EPS near $-0.26. The estimate reflects 7 contributing analysts.
SLNCF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Silence Therapeutics has seen recent insider buying, signaling confidence from within the company. This often translates to positive sentiment in the market.
- The gene therapy space is hot right now, and Silence Therapeutics' focus puts them in a favorable position to attract investor attention.
- Social media buzz indicates increased interest in Silence Therapeutics, with more users discussing its potential compared to competitors.
- The company's strategic partnerships are gaining traction, suggesting a strong foundation for future growth and market expansion.
Bear Case
- The gene therapy sector is crowded, and Silence Therapeutics faces stiff competition from larger, more established players.
- Community sentiment, while positive, shows some skepticism about the timeline for Silence Therapeutics' clinical trials.
- Recent market volatility has made investors risk-averse, potentially impacting smaller biotech companies like Silence Therapeutics more significantly.
- Despite insider buying, some are concerned about the company's cash burn rate and potential need for future funding rounds.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $422,000 | -$15M | -$0.11 |
| Q4 2025 | $34,000 | -$12M | -$0.08 |
| Q3 2025 | $159,000 | -$21M | -$0.15 |
Based on FMP financials and quantitative analysis
SLNCF Latest News
No recent news available for SLNCF.
SLNCF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SLNCF.
Price Targets
Wall Street price target analysis for SLNCF.
SLNCF MoonshotScore
What does this score mean?
The MoonshotScore rates SLNCF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Iain Gladstone Ross
CEO
Iain Gladstone Ross serves as the CEO of Silence Therapeutics plc. His background includes extensive experience in the pharmaceutical and biotechnology industries. Prior to joining Silence Therapeutics, Ross held leadership positions at various companies, focusing on strategic development, commercialization, and financial management. His expertise spans across multiple therapeutic areas, including oncology, cardiovascular, and metabolic diseases. Ross's educational credentials and previous roles have equipped him with a comprehensive understanding of the drug development process and the challenges faced by biotechnology companies.
Track Record: Since becoming CEO, Iain Gladstone Ross has focused on advancing Silence Therapeutics' clinical pipeline and securing strategic partnerships. Key achievements include progressing SLN360 and SLN124 into Phase I clinical trials and expanding collaborations with AstraZeneca, Mallinckrodt, and Hansoh Pharmaceutical. These initiatives have strengthened the company's financial position and validated the potential of its mRNAi GOLD platform.
SLNCF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Silence Therapeutics plc may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies on this tier may have limited reporting requirements, which can make it more difficult for investors to access comprehensive information. Trading on the OTC Other tier is generally associated with higher risk and lower liquidity compared to stocks listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Lower trading volume and liquidity.
- Greater price volatility and potential for manipulation.
- Higher risk of fraud or mismanagement.
- Limited regulatory oversight and investor protection.
- Verify the company's financial statements and reporting practices.
- Review the company's management team and board of directors.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Collaboration agreements with reputable pharmaceutical companies (AstraZeneca, Mallinckrodt, Hansoh Pharmaceutical).
- Clinical pipeline of product candidates in Phase I trials.
- Experienced management team with expertise in RNA therapeutics.
- Focus on developing innovative RNA therapeutic technologies.
SLNCF Healthcare Stock FAQ
What does the AI Score mean for SLNCF?
SLNCF holds an AI Score of 48/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Silence Therapeutics plc is a biotechnology company focused on developing novel RNA therapeutics. Their mRNAi GOLD platform targets disease-associated genes in hematology, cardiovascular, …
What does Silence Therapeutics plc do?
Silence Therapeutics plc is a biotechnology company specializing in the development of RNA therapeutics, primarily focused on hematology, cardiovascular, and metabolic diseases. The company's core technology is its mRNAi GOLD platform, which utilizes short interfering RNA (siRNA) molecules to target and degrade messenger RNA (mRNA) that encodes specific disease-related proteins.
What do analysts say about SLNCF stock?
Analyst coverage of SLNCF stock is limited due to its OTC listing and relatively small market capitalization. However, analysts generally view Silence Therapeutics' RNA therapeutic platform and clinical pipeline as promising. Key valuation metrics include the potential market size for its lead product candidates, the success rate of its clinical trials, and the value of its strategic partnerships.
What are the main risks for SLNCF?
The main risks for Silence Therapeutics plc include the inherent uncertainties associated with drug development, particularly the potential failure of clinical trials. The company's reliance on external funding and partnerships also poses a risk, as any disruption in these relationships could impact its financial stability and development programs. Competition from other biotechnology companies developing RNA therapeutics is another significant risk.
What are the key factors to evaluate for SLNCF?
Silence Therapeutics plc (SLNCF) holds an AI score of 48/100 (low). Silence Therapeutics presents a compelling, albeit high-risk, investment thesis centered on its innovative mRNAi GOLD platform and its pipeline of RNA therapeutics. Not financial advice.
How frequently does SLNCF data refresh on this page?
SLNCF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SLNCF's recent stock price performance?
Silence Therapeutics plc (SLNCF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary mRNAi GOLD platform for targeted RNA interference. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SLNCF overvalued or undervalued right now?
Silence Therapeutics plc (SLNCF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SLNCF before investing?
Before investing in Silence Therapeutics plc (SLNCF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-17.
- OTC market data may be less reliable than data from major exchanges.
- AI analysis pending for SLNCF may provide additional insights in the future.